Decidualization of human endometrial stromal cells requires steroid receptor coactivator-3
Vineet K. Maurya1 
Maria M. Szwarc1 
David M. Lonard1 William E. Gibbons2 
San-Pin Wu3 
Bert W. O’Malley1 Francesco J. DeMayo3 John P. Lydon1*
- 1Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, United States
- 2Department of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX, United States
- 3Reproductive and Developmental Biology Laboratory, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, United States
Steroid receptor coactivator-3 (SRC-3; also known as NCOA3 or AIB1) is a member of the multifunctional p160/SRC family of coactivators, which also includes SRC-1 and SRC-2. Clinical and cell-based studies as well as investigations on mice have demonstrated pivotal roles for each SRC in numerous physiological and pathophysiological contexts, underscoring their functional pleiotropy. We previously demonstrated the critical involvement of SRC-2 in murine embryo implantation as well as in human endometrial stromal cell (HESC) decidualization, a cellular transformation process required for trophoblast invasion and ultimately placentation. We show here that, like SRC-2, SRC-3 is expressed in the epithelial and stromal cellular compartments of the human endometrium during the proliferative and secretory phase of the menstrual cycle as well as in cultured HESCs. We also found that SRC-3 depletion in cultured HESCs results in a significant attenuation in the induction of a wide-range of established biomarkers of decidualization, despite exposure of these cells to a deciduogenic stimulus and normal progesterone receptor expression. These molecular findings are supported at the cellular level by the inability of HESCs to morphologically transform from a stromal fibroblastoid cell to an epithelioid decidual cell when endogenous SRC-3 levels are markedly reduced. To identify genes, signaling pathways and networks that are controlled by SRC-3 and potentially important for hormone-dependent decidualization, we performed RNA-sequencing on HESCs in which SRC-3 levels were significantly reduced at the time of administering the deciduogenic stimulus. Comparing HESC controls with HESCs deficient in SRC-3, gene enrichment analysis of the differentially expressed gene set revealed an overrepresentation of genes involved in chromatin remodeling, cell proliferation/motility, and programmed cell death. These predictive bioanalytic results were confirmed by the demonstration that SRC-3 is required for the expansion, migratory and invasive activities of the HESC population, cellular properties that are required in vivo in the formation or functioning of the decidua. Collectively, our results support SRC-3 as an important coregulator in HESC decidualization. Since perturbation of normal homeostatic levels of SRC-3 is linked with common gynecological disorders diagnosed in reproductive age women, this endometrial coregulator—along with its new molecular targets described here—may open novel clinical avenues in the diagnosis and/or treatment of a non-receptive endometrium, particularly in patients presenting non-aneuploid early pregnancy loss.
Introduction
After embryo aneuploidy, parental chromosomal translocations, maternal thrombophilic anomalies, immunological disorders, and obvious uterine ultrastructural abnormalities are excluded as etiologic contributors, implantation failure intrinsic to the endometrium is commonly suspected as an underlying cause of early pregnancy loss [EPL (1)] and recurrent pregnancy loss [RPL (2)], the latter defined as the loss of two or more consecutive pregnancies in the first trimester (2–5). Accordingly, pregnancy success rates currently achieved by natural or assisted conception for women at high-risk for EPL or RPL can only be increased by an improved understanding of the cellular and molecular mechanisms that control endometrial function during the periimplantation period.
Soon after embryo attachment and the early stages of implantation, further invasion into the maternal compartment requires a functional decidua (6). Formation of the decidua entails progesterone-dependent transformation of endometrial stromal fibroblasts into specialized polygonal epithelioid decidual cells with ploidy; a process termed decidualization (7). Encapsulating the invading embryo, tightly adherent decidual cells form a decidual matrix that supports the development of the hemi-allogeneic conceptus. Decidual support includes providing histotrophic nutrition, protecting against physiological stressors, and promoting an immunotolerant microenvironment. Superimposed on these functions, the human decidua acts as a biosensor in which non-viable embryos are negatively selected (8, 9). Moreover, the decidua recruits innate immune cells [particularly uterine natural killer (uNK) cells (10)] to control the orderly invasion of the trophoblast into the maternal compartment and to orchestrate spiral arteriole remodeling that is essential for normal uteroplacental perfusion (11). In addition, uNK cells target and clear acute senescent decidual cells from the mature decidual cell population to maintain a healthy decidua (12).
During the first trimester, the above decidual functions emerge early in a series of cellular and molecular events that sequentially progress in the endometrium to advance the implanting embryo to hemochorial placentation. Accordingly, inadequate decidualization not only causes fetal demise at an early stage of gestation but is linked to a broad range of gestational complications that manifest in subsequent trimesters; these include early fetal miscarriage due to placental insufficiency, placenta accreta, fetal growth restriction, preeclampsia, and pre-term birth (13). Therefore, identifying new molecular signals that are essential for decidualization is critical to furnishing novel mechanistic insights that may lead to the development of more efficacious mechanism-based molecular diagnostics and/or precision therapies to improve the outcome of natural pregnancies as well as pregnancies conceived through assisted reproductive technologies.
The steroid receptor coactivator (SRC)/p160 family is composed of three pleiotropic coactivators (SRC-1, SRC-2, and SRC-3) (14), also known as NCOA1, NCOA2, and NCOA3 respectively. Members of the SRC/p160 family control a broad spectrum of physiologies that include (but are not limited to) metabolism, circadian rhythms, immunology, and parturition (15–20). Such SRC multifunctionality is attained through a complex functional domain structure, encompassing diverse protein-protein interaction regions that are highly responsive to posttranslational modifications (PTMs) (21, 22). Originally discovered as coactivators for nuclear receptor mediated signaling (23), SRCs are now known to control numerous non-nuclear receptor signaling pathways (14, 24). As documented for other physiological systems, members of the SRC family have been shown to play important roles in uterine biology and pathobiology (24). Here, we report that SRC-3 is critical for decidualization of human endometrial stromal cells (HESCs) in culture. Apart from a block in the signature morphological cellular changes that normally accompany HESC decidualization, SRC-3 depletion results in a markedly diminished induction of the majority of molecular biomarkers implicated in the decidualization process. Analysis of RNA profiling experiments underscores the importance of SRC-3 as a transcriptional coregulator that enables the pre-decidual HESC to appropriately respond to the deciduogenic stimulus through coregulator support of a genome-wide transcriptional program.
Materials and methods
Human endometrial tissue and immunohistochemistry
Using a pipelle suction curette, human endometrial biopsies were collected under sterile conditions from the uterine fundus of healthy women of reproductive age (27–38 years old). Participants had a normal uterus as evaluated by transvaginal ultrasound and were not receiving hormone treatment for at least 3 months before tissue biopsy. Endometrial tissue was biopsied during the proliferative (n = 6) or secretory (n = 5) phases of the cycle. The timed cycle phase was determined by the study participants using home ovulation test kits, and cycle stage of the resultant biopsy tissue was confirmed by histological analysis (25–27). Written informed consent was provided by the volunteers before the biopsy procedure, which was conducted in accordance with a protocol prospectively approved by the Institutional Review Board (IRB) at Baylor College of Medicine and in accordance with the guidelines of the Declaration of Helsinki (28).
For immunohistochemical analyses, tissues were fixed overnight in 4% paraformaldehyde in phosphate-buffered saline (PBS) before paraffin embedding and sectioning onto slides. Immunohistochemical detection of SRC-3 was achieved using a primary rabbit monoclonal antibody against human SRC-3 [Cell Signaling Technology Inc., Danvers, MA (#2126); diluted 1 : 400] followed by incubation with a horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody [Vector Laboratories Inc., Burlingame CA (P-1,000); diluted 1 : 200]. Peroxidase activity was detected with the Vectastain Elite ABC-HRP kit (Vector Laboratories Inc.). Following immunostaining, tissue sections were counterstained with hematoxylin before applying Permount mounting solution (Fisher Scientific Inc. (SP 15–500) to affix coverslips.
Mouse xenograft studies
As previously described (29), singly dispersed endometrial cells [SDECs (containing stromal and glandular epithelial cells)] were prepared from human endometrial tissue biopsied during the proliferative phase of the cycle (n = 6). Using a Hamilton microliter syringe [Hamilton Company, Reno, NV (#95-901)], 5 × 105 SDECs in 5–10 ul of sterile Dulbecco's Modified Eagle Medium (DMEM) were injected beneath the renal capsule of both kidneys of ovariectomized scid-beige immunocompromised host mice [Taconic Biosciences Inc., Rensselaer, NY (#CBSCBG)]; n = 3 per biopsy sample. Two weeks prior to injection, host mice were ovariectomized and subcutaneously implanted within the intrascapular region with a 90 day slow release pellet containing (1.5 mg 17 β-estradiol (E2)/pellet; Innovative Research of America Inc. Sarasota FL (#E-121)) (29). For E2 plus progesterone (P4) treatment, host mice were treated with E2 for 8 weeks before receiving a daily injection of P4 (1 mg P4/100 ul sesame oil) for 14 days. Following hormone treatment, reconstituted human endometrial tissue engrafted within the murine kidney capsule were fixed and processed for immunohistochemical analysis as described above.
Accredited by AAALAC (Association for the Assessment and Accreditation of Laboratory Animal Care), scid beige host mice were housed in a germ-free facility in the vivarium at Baylor College of Medicine, which is operated and controlled by the Center for Comparative Medicine. Studies with mice followed the guidelines detailed in the Guide for the Care and Use of Laboratory Animals [published by the National Research Council (Eighth Edition 2011)]. Prior to conducting experiments, animal research protocols were approved by the Institutional Animal Care and Use Committee (IACUC) at Baylor College of Medicine.
Cell culture
The immortalized human endometrial stromal cell (T-HESC) line was obtained from the American Type Culture Collection [ATCC (CRL4003)] and maintained in phenol-red free DMEM/F12 medium supplemented with 10% charcoal/dextran-treated (stripped) FBS (sFBS: Sigma-Aldrich Inc., St. Louis, MO), 1% ITS-A (insulin, transferrin, selenite and sodium pyruvate), 500 ng/ml puromycin, 100 units/ml penicillin, and 0.1 mg/ml streptomycin (ThermoFisher Scientific Inc., Waltham, MA); medium was changed every other day. The authenticity of the T-HESC line was confirmed by short tandem repeat (STR) profiling by the ATCC cell line authentication service.
Transfection of small interfering RNAs and in-vitro decidualization
Cells were cultured in six-well plates in triplicate before transfection with sixty picomoles of the non-targeting [NT (scrambled control sequence)] siRNA [GE Healthcare Dharmacon Inc., Lafayette, CO (D-001810-10-05)] or siRNA targeting SRC-3 [Dharmacon Inc., (L-00 3759-00-0005)], using the Lipofectamine RNAiMAX transfection reagent (Invitrogen Inc., Carlsbad CA) (30). Forty-eight hours post-transfection of siRNAs, T-HESCs were cultured in deciduogenic medium to stimulate decidualization (100 nM 17β-estradiol [Sigma-Aldrich Inc. (E1024)], 10 μM medroxyprogesterone acetate (MPA [Sigma-Aldrich Inc. (M1629)], and 50 μM N6, 2′-O-dibutyryladenosine 3′, 5′ cyclic monophosphate sodium salt [Sigma-Aldrich Inc. (D0260)] in 1× Opti-MEM reduced serum medium, containing 2% charcoal-stripped FBS (hereon referred to as EPC medium); EPC medium was changed every 48 h.
Immunocytochemistry
After transfection with either NT or SRC-3 siRNAs, T-HESCs were cultured in EPC medium on coverslips coated with poly-L-lysine [Sigma-Aldrich Inc. (P4707)]. Following a specified time period of culture, T-HESCs were fixed on coverslips with 4% paraformaldehyde in PBS for 15 min at room temperature. Following fixation, cells were washed three times with PBS before permeabilization with 0.1% Triton X-100 in PBS at room temperature for 20 min. Permeabilized cells were washed with PBS, then blocked with 2% bovine serum albumin in PBS for 1 h at room temperature before incubation overnight at 4°C with a primary antibody against human SRC-3 [Cell Signaling Technology, Inc. (#2126); 1 : 200 dilution]. After washing with PBS, T-HESCs were incubated with the Alexa Fluor 594-conjugated secondary antibody [Life Technologies, (A21207); 1 : 500 dilution] and Alexa Fluor 488 Phalloidin [Invitrogen Inc., (A12376)] for 1 h at room temperature, washed, and then mounted with Vectashield Antifade mounting medium with 4′, 6′-diamidino-2-phenylindole [DAPI; Vector Laboratories Inc., (H-1200-10)]. Raw images were captured using a color chilled AxioCam MRc5 digital camera attached to a Carl Zeiss AxioImager A1 upright microscope equipped for epifluorescence detection (Zeiss Inc., Jena, Germany). Post image processing and annotation for the purposes of data presentation were performed using the latest versions of the Photoshop and Illustrator software programs provided within Adobe Creative Suite (Adobe Systems Inc., San Jose CA).
Quantitative real-time polymerase chain reaction
Cells were lysed in RNA lysis buffer before total RNA was isolated with the Purelink RNA Mini Kit [ThermoFisher Scientific Inc. (#12183020)]; the Nano-Drop 2000 UV/Visual spectrophometer (ThermoFisher Scientific Inc.) was used for RNA quantification. Total RNA (1 µg) was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit [ThermoFisher Scientific Inc. (#4368814)]. Amplified cDNA was diluted to a concentration of 10 ng/µl before quantitative real time PCR (qPCR) was performed; qPCR was performed using the Fast TaqMan 2X Mastermix (Applied Biosystems/Life Technologies, Grand Island, NY). The TaqMan assays used in this study are listed in Table 1. All qPCR experiments were performed using the 7,500 Fast Real-time PCR system (Applied Biosystems/Life Technologies, Grand Island, NY); the delta-delta cycle threshold was used to normalize expression to the 18S reference.
Table 1. List of human taqman expression assays used in these studies.
Genome-wide RNA expression profiling
Genome-wide RNA-sequencing (RNA-seq) and analysis were performed as described (30, 31). Briefly, total RNA purity and integrity were assessed using the NanoDrop spectrophotometer (ThermoFisher Scientific Inc.) and the 2,100 Bioanalyzer with RNA chips (Agilent Technologies, Santa Clara, CA) respectively. Only RNA samples scoring a RNA integrity number (RIN) of 8 or greater were included in subsequent RNA profiling experiments. For each experimental group, RNA samples from two replicates were used. Total RNA was reverse transcribed using the Ovation RNA-seq System V2 [Tecan Genomics Inc., Redwood City CA (#7102-32)]. For these experiments, cDNA libraries were generated with the Nextera DNA Flex Library Prep and the Nextera DNA CD indexes Kits [Illumina Inc., San Diego CA (#20018704)]. Using the Illumina NovaSeq 6,000 system, cDNA libraries were sequenced to a 50-nucleotide read length in the paired end format. Raw reads were processed using the Partek Flow Genome Analysis Software [Partek Inc., St. Louis, MO (version 10.0.21.0801)]. Reads for ribosomal and mitochondrial DNAs were removed by Bowtie 2 software (version 2.2.5), followed by base trimming with reference to quality scores with default parameters. Read alignment to the human genome hg38 was carried out using HISAT2 software (version 2.1.0). Both singleton and unaligned reads were removed using the default parameters set within the Partek Flow Genomics Analysis Software (Partek Inc.). Aligned and filtered reads were quantified to the National Center for Biotechnology Information RefSeq Transcripts 100 (2021-11-01), using the quantify-to-annotation model [(Partek E/M) function with default parameters] in Partek Flow (Partek Inc.). Gene counts were normalized to fragments per kilobase of exon per million mapped fragments (FPKM). For hierarchical clustering, the pheatmap package in R was used to draw the clustered heatmap based on FPKM values. Principal component analysis (PCA) and lists of differentially expressed genes were generated by the Partek Genomics Suite 7.0 (Partek Inc.).
The Bioconductor package EdgeR identified differentially expressed genes between the control and test group (32). The false discovery rate (FDR) of differentially expressed genes between the two groups was determined by Benjamini and Hochberg analysis (33). Differential gene expression between the two groups with a FDR value ≤0.05 and an absolute fold change (IFCI) ≥ 1.5 was considered significant and used further to identify affected pathways (34). Gene ontology enrichment analysis was conducted using the DAVID (Database for Annotation, Visualization, and Integrated Discovery) functional annotation clustering tool (http://david.abcc.ncifcrff.gov/) (35). Overrepresented established gene sets were identified by Gene Set Enrichment Analysis (GSEA; http://software.broadinstitute.org/gsea/) (36, 37). Hallmark gene sets from the Molecular Signatures Database (MSigDB) were used in these GSEA studies (38).
Immunoblotting
Protein (20 μg) from cell lysates was resolved on 10% or 4%–15% sodium dodecyl sulfate-polyacrylamide (SDS-PAGE) gels before transfer to polyvinylidene difluoride (PVDF) membranes. After protein transfer, PVDF membranes were blocked for 1 h with 5% non-fat dry milk [Santa Cruz Biotechnology Inc., Dallas, TX; (# SC-2324)] in Tris-buffered saline with Tween 20 (TBS-T) and incubated overnight at 4°C with the following primary antibodies: anti-SRC-3 [Cell Signaling Technology, Inc., (#2126)] diluted 1:1,000 and anti-β-actin [Novus Biologicals, Piscataway, NJ; (#NB10056874T)] diluted 1:10,000 in 5% non-fat milk in TBS-T. Immunoblots were then probed with anti-rabbit IgG secondary antibody (ThermoFisher Scientific Inc.; [#A27036 (1:5,000 dilution)] or anti-mouse IgG [Cell Signaling Technology, Inc.; #7076 (1:10,000 dilution)] secondary antibodies conjugated with HRP in 5% non-fat milk in TBS-T for 1 h at room temperature. The following primary antibodies were used to detect SRC-1 (anti-human SRC-1 rabbit monoclonal; Cell Signaling Technology Inc., #2191) and SRC-2 (anti-human SRC-2 mouse monoclonal antibody; BD Biosciences Inc. #610984). The primary antibody against the phospho-serine (S857) residue in human SRC-3 was obtained from Cell Signaling Technologies Inc. (#P57249 PP5). Chemiluminescence was detected with the SuperSignal West Pico PLUS Chemiluminescent Substrate (ThermoFisher Scientific, Inc.; #1863097). Immunoreactive bands were digitally imaged using the Azure 600 Imaging Systems (Azure Biosystems, Sierra Court, Dublin, CA). Densitometric analysis of immunoreactive bands corresponding to SRC-3 and β-actin (loading control) was performed using ImageJ software [version 1.53t (https://imagej.nih.gov)], a publically available Java-based image processing program.
Cell proliferation/viability assay
At a density of 3 × 103 cells per well, cells were seeded in 96-well culture plates in triplicate. Cells transfected with siRNAs for 48 h were further cultured for 0, 24, 48, 72 or 96 h before cell proliferation was measured using the CellTiter 96® Non-Radioactive Cell Proliferation Assay kit [Promega Inc. Madison, WI; (#G4000)] (30). Following a predetermined time period in culture, 15 μl of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT); Promega, Madison, WI) was added to each well to a final concentration of 0.5 mg/ml. In the dark, cells were then incubated at 37 °C for an additional three hours. Following supernatant removal, formazan crystals were dissolved by the addition of the stop/solubilizing solution {100 µl [dimethyl sulfoxide (DMSO)/well]}. The absorbance of the final mixture was recorded at 570 nm (the formazan absorbance maximum) using the Multiskan FC Microplate Photometer (Thermo Scientific Inc., #51119000). The mean absorbance at “N” time point/mean absorbance at 0 h (N = 24, 48, 72, and 96 h) calculated relative cell proliferation (30). Each experiment was repeated three times with at least three to five technical replicates for each treatment group.
Cell migration assay
As previously described (30), comparative cell migration was quantified using the in vitro wound-healing assay. Cells were seeded in six-well culture plates and cultured to 70%–80% confluency prior to siRNA transfection. A 200-μl sterile pipette tip generated a linear scratch (wound) in the middle of the cell monolayer within each well. After gentle washing to remove non-adherent cells, digital images were captured using an inverted phase-contrast microscope [EVOSTM XL Core Imaging System (ThermoFisher Scientific Inc. #AMEX1000)]. Following forty-eight hours of culture, the degree of wound closure per time point was recorded by digital image capture. The wound area was calculated by manual tracing the cell-free area within each captured image per experimental group using ImageJ software (https://imagej.nih.gov/ij/). Results were recorded as a percent of wound closure in comparison to control after a forty-eight hour culture period (percent cell migration area = wound width at 0 h – wound width at 48 h/wound width at 0 h). Each experiment was repeated three times with triplicates for each treatment group.
Transwell cell invasion assay
The Corning BioCoat Matrigel Invasion Chamber Kit [ThermoFisher Scientific Inc. (#354480)] was used for cell invasion assays (30). Following the forty-eight hour siRNA transfection period, T-HESCs were suspended in Opti-MEM medium. To the bottom of each transwell of the invasion chamber plate, culture medium with 20% FBS was added (0.6 ml). To test migration potential, suspended cells (8 × 104 cells/250 µl) were added to each transwell insert. After forty-eight hours, a cotton swab carefully removed cells on the upper surface of the transwell. Following fixation with 4% paraformaldehyde in PBS, migrated cells were stained with a crystal violet solution (30). Washed inserts were digitally imaged using a Zeiss stereo-microscope with an attached AxioCam MRC-5 digital camera (Zeiss Inc., Jena, Germany). Stained migrated cells were counted in four separate cell fields throughout the insert before an average number of migrated cells was calculated (30). Each experiment was repeated three times with triplicates for each treatment group.
Statistical analysis
Two-tailed unpaired Student t-tests with Welch's correction were used to estimate the statistical significance of differences between control and test groups. One-way ANOVA was used for multiple comparisons to analyze experiments containing more than two groups. Unless otherwise stated, data were graphically presented as mean ± standard deviation (SD). Differences with p-values <0.05 were considered statistically significant; asterisks represent the level of significance: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. Prism software version 9 (GraphPad Software Inc., San Diego CA) was used for the majority of the reported statistical analyses.
Results
Steroid receptor coactivator-3 is expressed in human endometrial epithelial and stromal cells
Immunohistochemical analysis revealed that SRC-3 protein is expressed in nuclei of glandular epithelial and stromal cells of human endometrial tissues biopsied during the estrogen-dominant proliferative phase of the menstrual cycle (Figure 1A). In addition, SRC-3 expression was detected in the same endometrial cellular compartments during the progesterone-dominant mid-secretory phase of the cycle (Figure 1A). Although a moderate increase in endometrial epithelial and stromal SRC-3 expression is qualitatively observed during the secretory phase of the cycle, the overall expression profile of SRC-3 does not significantly change between the two cycle stages. These results indicate that estrogen and progesterone do not significantly control SRC-3 expression in the human endometrium. This conclusion is further supported by xenograft experiments that entailed using SDECs derived from human endometrial tissue biopsies transplanted beneath the renal capsule of ovariectomized immunocompromised scid beige mice, which were then treated with estrogen (E2) or estrogen plus progesterone (E2P4) (Supplementary Figure S1). Using this controlled hormone treatment model, the SRC-3 expression profile did not markedly change between E2 and E2P4 treatment (Supplementary Figure S1). The above conclusions generally agree with conclusions drawn from previous investigations that used a different primary SRC-3 antibody (40) or studies that investigated SRC-3 expression only at the RNA level (41). The expression of SRC-3 protein was also detected in nuclei of cultured T-HESCs (Figure 1B). The expression of SRC-3 was detected in all T-HESCs irrespective of whether these cells were in the pre-decidual ([Day 0 (EPC)] or decidualized [Day 6 (EPC)] state.
Figure 1. Expression of SRC-3 in human endometrial cells (A) left column of panels shows low and high power magnification images (top and bottom panels respectively) of human endometrial tissue biopsied during the estrogen-dominant proliferative phase of the menstrual cycle, which was immunohistochemically stained for SRC-3 expression. Note that most glandular epithelial (GE) cells express nuclear localized SRC-3 while stromal cells express lower levels of SRC-3 at this stage of the cycle. Right column of panels displays low and higher magnification images (top and bottom panels respectively) of human endometrial tissue biopsied during the progesterone-dominant secretory phase and stained for SRC-3 expression. Expression of nuclear SRC-3 is clearly detected in the GE cells, which exhibit a distinctive tortuous morphology at this stage of the cycle. Nuclear expression of SRC-3 in the stroma is clearly observed in the majority of cells. Scale bars in the top and bottom left panels apply to the top and bottom right panels respectively. (B) The left two columns show cultured T-HESCs stained with DAPI (blue nucleus) or DAPI (blue) plus phalloidin (green; binds F-actin) on day 0 and 6 of EPC treatment; arrowhead denotes nucleus of T-HESC. On day 0 of EPC treatment, T-HESCs exhibit a fibroblastic morphology with F-actin fibers orientated parallel to each other. Following six days of EPC treatment, note the conspicuous spatial disorganization of the F-actin fibers indicative of cellular transformation from a fibroblastoid to an epithelioid cell morphology (39). The two columns on the right show the same cells immunofluorescently stained for SRC-3 expression [red (arrowhead)] or SRC-3 (red) plus phalloidin (green). Note that SRC-3 is expressed in all T-HESCs at days 0 and 6 of EPC treatment with most of its expression localized to the nucleus (arrowhead). Scale bar applies to all panels.
Expression levels of SRC-3 in T-HESCs do not significantly change during the decidualization process
Although the level of prolactin (PRL; an established decidual biomarker (42) significantly increases as T-HESCs decidualize with time, the level of SRC-3 expression does not markedly change (both at the RNA and protein level) during the time course of treatment with the deciduogenic hormone stimulus (EPC) (Figures 2A–D). These results also agree with expression data obtained from analyzing a publically available RNA-seq dataset (GEO accession: GSE104721) (44). This study used cultured primary HESCs either untreated (day 0 EPC) or treated with EPC for 4 days (44) (Figure 2E). Our analysis of this dataset shows that SRC-3 mRNA levels do not significantly change in primary HESCs either in the pre-decidual or decidualized state. While SRC-3 protein levels do not change in the pre-decidual and decidualized HESC, the phosphorylation status of SRC-3 changes in response to the EPC deciduogenic stimulus (Supplementary Figure S2). These results suggest that SRC-3 functional activity may be modulated by EPC-induced PTMs rather than control of the absolute levels of SRC-3 protein. Interestingly, analysis of separate publically available RNA-seq dataset (GEO accession: GSE65099) (45) showed that SRC-3 RNA levels are significantly increased in the endometrium of patients diagnosed with RPL (Figure 2F), suggesting that perturbation of the homeostatic levels of SRC-3 may be linked to this endometrial pathology. It's important to note that dysregulation of SRC-3 expression is known as a critical causal factor in the genesis and progression of numerous tissue pathologies, including tumorigenesis and metastasis (14, 46, 47).
Figure 2. Expression levels of SRC-3 do not significantly change during T-HESC decidualization. (A) Schematic summarizes the experimental design of EPC decidualization of T-HESCs in culture. Following culture in standard culture medium for forty-eight hours, T-HESCs were switched to EPC medium to elicit decidualization over time. Cells were harvested at 0, 1, 2, 4, and 6 days following EPC administration for qPCR and western analysis. (B) As expected, the established PRL biomarker for decidualization (43) is significantly induced following EPC administration with time. (C) The expression levels of SRC-3 do not markedly change from day 0 to day 6 of EPC treatment. (D) The results in (C) are confirmed at the protein level by western analysis, which show there is minimal change in the levels of SRC-3 protein during T-HESC decidualization. (E) From a publicly available GEO dataset [GSE: 104721 (44)], raw transcript scores for SRC-3 (NCOA3) were calculated from HESCs cultured at day 0 (non-decidualized) and day 4 (decidualized) in deciduogenic medium. Note that SRC-3 transcript levels in T-HESCs do not significantly change following decidualization; n = 3 samples per treatment group. (F) The SRC-3 raw transcript scores from endometrial RNA obtained from women diagnosed with RPL compared with patients diagnosed with no RPL (control) (45); endometrial tissue was biopsied at the mid-secretory phase of the cycle. Original transcript data were obtained from the publically available RNA-seq dataset [GEO accession: GSE 65099 (45)]. Analysis reveals that SRC-3 RNA is significantly increased in endometrial tissue biopsied from RPL patients when compared to control patients. Results are displayed as the mean ± SE; n = 10 women per RPL and control groups.
Decidualization of T-HESCs requires SRC-3
Although SRC-3 is expressed in HESCs, the observation that SRC-3 levels do not significantly change following decidualization raises the question: Is SRC-3 functionally required for HESC decidualization? To address this question, we used an established T-HESC line (48–50), which has been extensively used to study numerous factors implicated in HESC decidualization (39, 51–54). Analysis by qPCR revealed that siRNA mediated silencing significantly reduced SRC-3 RNA levels in T-HESCs and resulted in near undetectable levels of SRC-3 protein, even after day 6 of EPC culture (Figures 3A,B). Importantly, SRC-3 knockdown in T-HESCs did not significantly change SRC-1 or SRC-2 expression at the RNA or protein level (Supplementary Figure S3). This result is important as we have demonstrated that SRC-2 is essential for decidualization of cultured HESCs as well as murine endometrial decidualization (55, 56). Conversely, we found that SRC-1 is not required for T-HESC decidualization (data not shown). At the cell morphology level (Figures 3C–F), SRC-3 knockdown resulted in the inability of T-HESCs to transform from a fibroblastoid to an epithelioid morphology following administration of the deciduogenic hormone cocktail (EPC). For these cell-based studies, phalloidin fluorescent detection of F-actin was used (39). Isolated from the “death cap” mushroom (Amanita phalloides), phalloidin irreversibly binds juxtaposed actin molecules within the F-actin filament assembly. In the case of NT siRNA knockdown, T-HESCs change cellular morphology from a pre-decidual fibroblastic cellular shape with an ordered parallel organization of F-actin filaments (39) to a polygonal shape that is typical of the decidual cell, underscored by a striking disorganized arrangement of F-actin filaments (Figures 3C,E). With SRC-3 siRNA knockdown, however, F-actin filaments remain parallel in T-HESCs following EPC treatment (Figures 3D,F), indicating that depletion of SRC-3 impairs the ability of T-HESCs to adopt the cellular morphology that characterizes a decidualized endometrial stromal cell (Figures 3D,F). Confirming the above qPCR and western results (Figures 3A,B), negligible levels of SRC-3 were immunofluorescently detected in T-HESCs following SRC-3 siRNA transfection (Supplementary Figure S4).
Figure 3. Decidualization of T-HESCs requires SRC-3 expression (A) siRNA mediated knockdown effectively reduces SRC-3 levels in T-HESCs both at day 0 and day 6 of EPC culture. The histogram's dark grey bar on the left indicates T-HESCs transfected with NT siRNAs whereas the light grey bars on the right denote T-HESCs transfected with SRC-3 siRNAs. Note the persistent knockdown of SRC-3 from day 0 to day 6 of EPC culture. (B) Top panel shows that the western data confirm the results shown in (A). Note the significant knockdown of SRC-3 protein to undetectable levels following transfection with siRNAs targeted to SRC-3 at day 0 and 6 of EPC treatment; β-actin serves as a loading control. Bottom panel shows that ImageJ analysis quantitatively confirms the western data shown in the top panel. The black and red dots for each bar in the histogram represent the number of technical replicates per time point/treatment group. Error bars denote a mean average of densitometric intensity per time point/treatment group ± standard deviation (SD); ** denote a p-value ≤ 0.01. (C,D) show T-HESCs at day 0 of EPC treatment that are transfected with siRNAs targeting NT or SRC-3 respectively. Cells were immunofluorescently stained with DAPI (blue nuclei) and phalloidin [green fibers; binds F-actin (arrowhead)]. Note the typical parallel arrangement of F-actin filaments in the pre-decidual fibroblastic T-HESCs at this early stage of EPC culture. (E) and (F) display T-HESCs at day 6 EPC treatment, which were transfected with siRNAs targeting NT and SRC-3 respectively. Note in (E) the expected spatial disorganized pattern of F-actin filaments in NT siRNA transfected T-HESCs as cells transform from a fibroblastoid to an epithelioid decidual cell morphology following six days of EPC culture. (F) Under similar culture conditions in (E), T-HESCs transfected with siRNAs targeting SRC-3 fail to show this F-actin disorganized pattern and continue to display the ordered F-actin parallel pattern as observed in the pre-decidual stromal fibroblast shown in [D (white arrowhead)]. Scale bar in (C) applies to (D–F).
The above cell morphology results were supported at the molecular level by the significant reduction by SRC-3 knockdown in T-HESCs in the induction of a gene subset that has been previously documented as important for decidualization or for cellular functions of the decidual cell (Figure 4). These genes include: prolactin [PRL (42)]; insulin like growth factor binding protein-1 [IGFBP1 (57)]; heart and neural crest derivatives expressed 2 [HAND2 (58, 59)]; forkhead box 1 [FOXO1 (12, 60)]; homeobox A10 [HOXA10 (61)]; homeobox A11 [HOXA11 (62)]; SRY-Box transcription factor 4 [SOX4 (63)],; somatostatin [SST (64)], and scavenger receptor class A member 5 [SCARA5 (65)]; DECORIN [DCN (39)]; interleukin 15 [IL15 (66)]; and PGR, progesterone receptor (67). Interestingly, PGR [and WNT4 (68, 69) (data not shown)] levels did not change with SRC-3 knockdown, indicating that a decrease in PGR levels is not the mechanism by which the decidual induction of the above genes is changed as a result of SRC-3 depletion, and that not all genes associated with decidualization are affected by SRC-3 depletion.
Figure 4. Depletion of SRC-3 in T-HESCs results in a significant attenuation in the induction of established decidual cell markers following EPC culture. Quantitative real-time PCR reveals that siRNA mediated SRC3 knockdown resulted in a marked reduction in the induction of the following established molecular targets: PRL, prolactin; IGFBP-1, insulin growth factor binding protein-1; HAND2, heart and neural crest derivative expressed 2; FOXO1, forkhead box 1; HOXA10, homeobox A10; HOXA11, homeobox A11; SOX4, SRY-Box transcription factor 4; SST, somatostatin; SCARA5, scavenger receptor class A member 5; DCN; decorin; IL15, interleukin 15; and PGR, progesterone receptor.
Transcriptomic analyses of T-HESCs depleted of SRC-3 prior to receiving the deciduogenic stimulus
Given SRC-3 is required for T-HESC decidualization (Figures 3, 4), RNA-seq analysis was performed to determine whether the T-HESC transcriptome is significantly changed as a result of SRC-3 depletion. Such a transcriptome change is predicted to compromise the T-HESC's ability to correctly respond to the deciduogenic signal and execute normal functions of a decidual cell. The overall RNA-seq experimental design is shown (Figure 5A). Briefly, T-HESCs were transfected with NT siRNA (control) or SRC-3 siRNAs for forty-eight hours. Instead of switching to the deciduogenic EPC medium, transfected cells (at day 0 EPC) were processed for RNA-seq analysis (Figure 5A).
Figure 5. The SRC-3 dependent transcriptome in T-HESCs prior to receiving the deciduogenic hormone stimulus (A) the experimental design of the RNA-seq experiment showing that T-HESCs were transfected with NT or SRC-3 siRNAs for forty-eight hours prior to being harvested for total RNA isolation; note: T-HESCs did not receive the EPC medium. Cells were harvested from two wells of a six well plate for each replicate; two replicates per NT and SRC-3 siRNA treatment group were used for these RNA-seq experiments. (B) Heatmap of clustered genes with the same expression level differentially expressed (up or down) between the NT siRNA and SRC-3 siRNA groups. Using a FDR <0.05 and an IFCI > 1.5 cutoff, 226 genes were differentially expressed (73 down and 153 up) between the NT and SRC-3 siRNA groups. The 226 genes were clustered and displayed as a heat map, in which each horizontal row represents a single gene. Warmer and cooler colors (i.e. reds and blues respectively) represent higher and lower expression respectively: the vertical color key on the right indicates the color intensity with normalized expression values.
Duplicate samples per treatment group were used for the RNA-seq experiment; cells were isolated from two wells of a six-well plate per sample. The complete list of genes differentially expressed between the two groups is reported in an Excel sheet in the supplementary section (Supplementary Folder S1). A total of 795 (499 upregulated and 296 downregulated) expressed genes were identified by RNA-seq were significantly changed (Supplementary Folder S1); 153 upregulated and 73 downregulated genes in this gene set reached the predetermined FDR (≤0.05) and FC (≥1.5) cutoffs. The FKPM values for all 795 genes were analyzed by PCA [Supplementary Folder S1 (PCA tab)]. The PCA showed that the NT siRNA- and SRC-3 siRNA-treatment groups were significantly separated in terms of their respective duplicates. Tables 2, 3 list the top 50 genes down and up regulated respectively that met the FDR (≤0.05) and FC (≥1.5) cutoffs whereas the expression heatmap (Figure 5B) shows the top 226 genes (153 upregulated and 73 downregulated) between the NT siRNA and SR-3 siRNA treatment groups. The above RNA-seq datasets were deposited in the NCBI GEO repository (GEO accession number: GSE210936).
Table 2. Top 50 downregulated genes with > 2 log2FC and ≤ 0.05 FDR in SRC-2 knockdown THESCs line.
Table 3. Top 50 upregulated genes with > 5 log2FC and ≤ 0.05 FDR in SRC-2 knockdown THESCs line.
Using the agglomeration and gene ontology (GO) tools in DAVID, genes in the differentially expressed gene set were grouped according to GO terms, which were further stratified into the following biological modules: biological processes, cellular components, and molecular functions (Figures 6A–D). Our analyses revealed a significant enrichment in the differentially expressed gene dataset for genes involved in mitotic phase cycle transition, chromatin remodeling, nucleosome organization, and DNA replication dependent nucleosome assembly (Figures 6A–D). Related to the above, the use of KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway annotation software showed that protein families involved in genetic information processing scored the highest in terms of number of genes assigned to a given biological process (Supplementary Figure S5). Interestingly, a review of the differential gene expression table (Supplementary Folder S1) uncovered a significant overrepresentation of genes encoding members of the core histone class of proteins, a subset of which was validated by qPCR (Figure 6E).
Figure 6. Gene ontology functional analyses of differentially expressed genes in T-HESCs following SRC-3 knockdown (A) gene ontology (GO) enrichment analysis of differentially expressed genes was achieved using the DAVID. The six significantly enriched GO terms (p < 0.05) in molecular function along with the ten top significantly enriched GO terms in biological processes and cellular component branches are presented. The adjusted p-values of the terms were –log10 transformed. (B–D) Dot plots of enriched genes within the differentially expressed gene set are stratified according to biological processes, cellular components, and molecular functions respectively. (E) Quantitative real time PCR analysis shows significant reduction in the induction of the following histone family members: H2AC21, H3C1, H3C7, H3C10, H4C3, and H4C4 in T-HESCs following SRC-3 knockdown.
Genes that are involved in cell proliferation, migration, and invasion were also enriched in the differentially expressed gene dataset (Figure 7A). For example, the Cell Communication Network (CCN) family of cysteine-rich matricellular proteins are extracellular matrix (ECM)-associated proteins that are active in a wide spectrum of biologies and pathobiologies (70). In particular, the CCN2 and CCN3 matricellar proteins underpin numerous cellular activities that range from mitogenesis, differentiation, survival, adhesion, migration, chemotaxis, angiogenesis, chondrogenesis, and wound healing (71, 72). Accordingly, CCN2 and CCN3 dysregulation is causal for a multitude of human pathobiologies, including tumorigenesis and metastasis (73, 74). Interestingly, these proteins have been implicated in female reproductive disorders, such as preeclampsia (75–77); however, their role in the normal endometrium is unclear. Also linked to cellular proliferation, migration and invasion in other physiologies, inhibin beta A (also known as INHBA) was originally recognized as a subunit for the closely related activin and inhibin glycoproteins, which exert opposing functional effects. However, INHBA perturbation alone has been associated with aggressive tumor behavior, including acceleration of cell proliferation, epithelial mesenchymal transition (EMT), migration and invasion (78–80). Noteworthy, INHBA has been detected in the human endometrium and endometrial pathologies (81, 82); however, the role of INHBA in the endometrial stromal cell remains an open question. In addition to inhibiting matrix metalloproteinases, tissue inhibitor of metalloproteinases 1 (TIMP1) can signal in a cytokine-like manner to influence numerous biological processes, which includes cellular proliferation, differentiation, apoptosis, angiogenesis, and oncogenesis (83–85). Although detected in murine and human endometrial tissue, TIMP1's role in endometrial function is currently unknown.
Figure 7. Proliferative and migratory properties of T-HESCs are significantly reduced following SRC-3 knockdown. (A) Quantitative real-time PCR analyses shows a significant reduction in the induction of CCN2, CCN3, INHBA, and TIMP1 following SRC-3 knockdown. (B) The MTT assay demonstrates that depletion of SRC-3 levels in T-HESCs markedly reduces this cell type's ability to maintain optimum cell viability/ proliferative capacity over time. (C) The wound healing assay demonstrated that SRC-3 knockdown resulted in a significant reduction in the migratory abilities of T-HESCs. Shown is a representative bright-field image of the migrated area (demarcated by dotted line) forty eight hours following the application of the scratch to the cell monolayer, previously transfected with either NT or SRC-3 siRNAs; scale bar applies to all images. (D) The histogram quantitatively displays the reduced migratory ability of T-HESCs following SRC-3 knockdown. Migratory ability of T-HESCs is reduced by at least 50% following SRC-3 knockdown (compare black bar (NT siRNA) with red bar (SRC-3 siRNA)). (E,F) Quantitative real time PCR and western immunoblot analyses confirm efficient SRC-3 knockdown in T-HESCs at the RNA and protein level respectively in these experiments. Results in (E) are displayed as ± SE and are representative of three independent experiments; *p-value <0.05; **p-value <0.01; ***p-value <0.001; and ****p-value < 0.0001. Western in (F) is representative of three separate experiments; β-actin was used as a loading control.
Although functionally validating these new genes in HESC decidualization is beyond the scope of the current study, the various cellular properties attributed to these genes provided the impetus to test whether SRC-3 controls these cell activities, specifically cell viability, migration, and invasive properties of HESCs, especially as SRC-3 controls these cellular functions in other physiologies and pathologies (86–88). To address the aforementioned, the MTT assay demonstrated that SRC-3 is necessary for full proliferative capacity of the T-HESC, and that the necessity for SRC-3 increases as the duration of culture lengthens (Figure 7B). In addition, SRC-3 is also essential for the known intrinsic migratory (Figures 7C–F) and invasive properties of endometrial cells (Supplementary Figure S6), cellular properties that are essential for a fully functional decidua in vivo (89–92).
Discussion
Originally discovered as an oncogenic coactivator (93), SRC-3 [also known as amplified in breast cancer 1 (AIB1)] is now recognized as a pivotal coactivator for a broad spectrum of physiological processes, ranging from metabolism, circadian rhythms to T cell biology (18, 94–96). Importantly, SRC-3 is implicated in female reproductive physiology and pathophysiology (24).
In the case of endometrial pathology, Lessey's group reported that SRC-3 levels (along with SRC-2 [also known as transcriptional intermediary factor 2 (TIF2)] are markedly elevated in epithelial and stromal cells of secretory-phase endometrial tissue biopsied from patients diagnosed with polycystic ovary syndrome (PCOS) (40). Apart from an increased susceptibility for endometrial cancer (97), PCOS patients are predisposed to additional reproductive sequelae, which include low cycle fecundity and a high miscarriage rate that can reach 60%–70% (98, 99). Independent studies have also shown that SRC-3 levels are strikingly elevated in hyperplastic and/or malignant human endometrial tissue (100–104).
In agreement with previous studies (40), we show here that SRC-3 is expressed in the glandular epithelial and stromal compartments of a healthy endometrium, and that endometrial SRC-3 expression does not significantly alter with cycle stage or with changes in hormone exposure (i.e., from an E2 to an E2 plus P4 environment). In the case of cultured T-HESCs, we found that neither SRC-3's spatial distribution nor expression level markedly changed during decidualization. Notable, however, endometrial SRC-3 levels are aberrantly elevated in a number of gynecological morbidities, which include endometrial hyperplasia and cancer (100, 101), PCOS (40), and endometriosis (105). Here, our bioinformatic analysis also showed that abnormally elevated levels of SRC-3 occur in endometrial tissue biopsied from patients diagnosed with RPL (Figure 2F). Therefore, these findings furnish tantalizing support for the proposal that unscheduled elevation of endometrial SRC-3 levels may serve as a biomarker for the emergence of these uterine pathobiologies. Interestingly, SRC-3's phosphorylation status in T-HESCs is altered between the pre-decidual and decidualized state. Specifically, the levels of SRC-3, which harbored phosphorylated serine residue 857 (S857), increased in decidual cells compared with pre-decidual cells. As phosphorylation of SRC-3 at residue S857 is known to modulate and extend coactivator potency in other physiological systems (22, 106, 107), this PTM event may signal a change in SRC-3 activation status between the pre-decidual and decidual cell. Future investigations will test whether this PTM (as well as other PTMs singly or in combination) is functionally important for SRC-3's role in decidualization and/or in the functional properties of the decidual cell following its development from a HESC progenitor.
By depleting pre-decidual HESCs of total SRC-3 protein, we demonstrated that SRC-3 is essential for these cells to transform into specialized decidual cells; the decidual defect could not be compensated by other SRC members. Importantly, the normal induction of the majority molecular signals tested—hormones, growth factors, transcription factors, and cytokines, which have been shown to be functionally important for this cellular transformation process (or for correct functioning of the decidual cell once formed), was significantly attenuated in response to diminished SRC-3 levels. Collectively, these results underscore the importance of SRC-3 in sustaining the pivotal transcriptional responses that manifest in HESCs, which ensure HESC development to a normally functioning decidual cell. Because the EPC-induction of transcription factors [i.e., HAND2 (58, 66)] and paracrine signals [i.e., IL15 (12, 66, 108–111)] is significantly attenuated in SRC-3 depleted HESCs, SRC-3 is required for optimum HESC intra- and extracellular signaling.
The derailment in the induction of these and other known transcriptional programming events in HESCs with a SRC-3 deficit provided the pretext to identify the early HESC molecular signals and associated biological processes that are compromised following reduction of SRC-3 levels. Specifically, the focus of the transcriptomic analysis was to determine the extent to which SRC-3 depletion would alter the transcriptome of the pre-decidual cell prior to receipt of the deciduogenic stimulus.
Significant reduction of SRC-3 levels in pre-decidual HESCs over a forty eight hour period resulted in a marked change in the transcriptome that normally exists at a time when these cells receive the deciduogenic hormone stimulus. Gene enrichment analysis revealed that the expression of genes involved in chromatin remodeling, organization and assembly of the nucleosome and control of DNA replication was significantly reduced in HESCs with reduced SRC-3 levels. Noteworthy was the significant reduction in the expression levels of core histone variants (i.e., H3AC21; H3C1; H3C7; H3C10; H4C3; and H4C4). From yeast to humans, histone homeostasis is essential for avoiding genomic stress, changes in global transcriptional output, premature replicative senescence and ageing (112–123). Normally, strict controls on histone gene expression levels are in place during the cell cycle to ensure direct coupling of DNA replication with canonical histone deposition (124–126). Interestingly, however, scheduled increases in histone content are associated with cellular differentiation and ploidy, both cellular processes that underpin HESC decidualization (127). Following SRC-3 knockdown, the reduction in the expression levels of core histone variants, along with other factors implicated in nucleosome organization and assembly, may in part contribute to the observed decrease in HESC proliferative capacity as cellular proliferation followed by differentiation is a requirement for completion of the decidualization process (7).
It should be noted that the above findings from our cell-based investigations have yet be confirmed by in vivo model systems. Female mice, which are deficient in SRC-3, exhibit dwarfism, delayed pubertal onset, attenuated mammary gland morphogenesis, striking metabolic impairments, and a severe subfertility defect (128). Because of the phenotypic complexity displayed by the whole body SRC-3 knockout mouse, we recently generated a conditional SRC-3 knockout mouse by crossing our Pgr-cre driver mouse with a mouse carrying the floxed SRC-3 allele (129, 130). Interestingly, the conditional SRC-3 knockout female mouse is infertile, and its endometrium fails to decidualize (unpublished data), supporting the in vitro studies described here.
In conclusion, our studies offer compelling support for an important role for SRC-3, which is independent of the other SRC family members, in HESC decidualization. Devoid of SRC-3, HESCs are less viable and lose significant proliferative, differentiative, motile, and invasive capabilities, cellular attributes that are necessary for either the development or function of the decidual cell. Given decidualization is critical for advancement of the implantation process toward placentation, further investigation of endometrial SRC-3 in periimplantation biology is predicted to furnish new molecular insights not only into normal endometrial function but also endometrial dysfunction that leads to early pregnancy loss.
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.
Ethics statement
The studies involving human participants were reviewed and approved by Institutional Review Board (IRB) at Baylor College of Medicine. The patients/participants provided their written informed consent to participate in this study. The animal study was reviewed and approved by Institutional Animal Care and Use Committee (IACUC) at Baylor College of Medicine.
Author contributions
Experiments and experimental design are attributed to VKM and JPL. Human endometrial tissue processing and histological analysis was performed by WEG and MMS. Human xenograft tissues were processed by SW and FJD. Genome-wide RNA sequencing and analysis was undertaken by SW and FJD. DML, BWO, FJD, and JPL conceptualized the original studies and subsequent experimental planning. Finally, JPL overall supervised the studies described herein. All authors contributed to the article and approved the submitted version.
Funding
The research was funded in part by the Intramural Research Program of the National Institute of Environmental Health Sciences: Project Z1AE8103311-01 (FJD) and National Institutes of Health (NIH)/National Institute of Child Health and Human Development (NICHD) grants: R01 HD-07857 and R01 HD-042311 to BWO and JPL respectively.
Acknowledgments
The authors thank Yan Ying and Rong Zhao for their invaluable technical expertise. The technical assistance of the National Institute of Environmental Health Science's Epigenomics and DNA Sequencing Core Facility is acknowledged. Finally, the authors thank CD Genomics, Shirley, New York USA for providing end-stage bioinformatic assistance.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/frph.2022.1033581/full#supplementary-material.
References
1. ASRM. Practice Committee of the American Society for Reproductive Medicine,. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril. (2020) 113(3):533–5. doi: 10.1016/j.fertnstert.2019.11.025
2. Dimitriadis E, Menkhorst E, Saito S, Kutteh WH, Brosens JJ. Recurrent pregnancy loss. Nat Rev Dis Primers. (2020) 6(1):98. doi: 10.1038/s41572-020-00228-z
3. Rai R, Regan L. Recurrent miscarriage. Lancet. (2006) 368(9535):601–11. doi: 10.1016/S0140-6736(06)69204-0
4. Bellver J, Simon C. Implantation failure of endometrial origin: what is new? Curr Opin Obstet Gynecol. (2018) 30(4):229–36. doi: 10.1097/GCO.0000000000000468
5. Ewington LJ, Tewary S, Brosens JJ. New insights into the mechanisms underlying recurrent pregnancy loss. J Obstet Gynaecol Res. (2019) 45(2):258–65. doi: 10.1111/jog.13837
6. Maurya VK, DeMayo FJ, Lydon JP. Illuminating the “black box” of progesterone-dependent embryo implantation using engineered mice. Front Cell Dev Biol. (2021) 9:640907. doi: 10.3389/fcell.2021.640907
7. Gellersen B, Brosens JJ. Cyclic decidualization of the human endometrium in reproductive health and failure. Endocr Rev. (2014) 35(6):851–905. doi: 10.1210/er.2014-1045
8. Brosens JJ, Salker MS, Teklenburg G, Nautiyal J, Salter S, Lucas ES, et al. Uterine selection of human embryos at implantation. Sci Rep. (2014) 4:3894. doi: 10.1038/srep03894
9. Teklenburg G, Salker M, Molokhia M, Lavery S, Trew G, Aojanepong T, et al. Natural selection of human embryos: decidualizing endometrial stromal cells serve as sensors of embryo quality upon implantation. PLoS One. (2010) 5(4):e10258. doi: 10.1371/journal.pone.0010258
10. Sojka DK, Yang L, Yokoyama WM. Uterine natural killer cells. Front Immunol. (2019) 10:960. doi: 10.3389/fimmu.2019.00960
11. Evans J, Salamonsen LA. Decidualized human endometrial stromal cells are sensors of hormone withdrawal in the menstrual inflammatory cascade. Biol Reprod. (2014) 90(1):14. doi: 10.1095/biolreprod.113.108175
12. Brighton PJ, Maruyama Y, Fishwick K, Vrljicak P, Tewary S, Fujihara R, et al. Clearance of senescent decidual cells by uterine natural killer cells in cycling human endometrium. Elife. (2017) 6:1–23. doi: 10.7554/eLife.31274
13. Cha J, Sun X, Dey SK. Mechanisms of implantation: strategies for successful pregnancy. Nat Med. (2012) 18(12):1754–67. doi: 10.1038/nm.3012
14. Xu J, Wu RC, O'Malley BW. Normal And cancer-related functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. (2009) 9(9):615–30. doi: 10.1038/nrc2695
15. Stashi E, Lanz RB, Mao J, Michailidis G, Zhu B, Kettner NM, et al. SRC-2 is an essential coactivator for orchestrating metabolism and circadian rhythm. Cell Rep. (2014) 6(4):633–45. doi: 10.1016/j.celrep.2014.01.027
16. O'Malley BW. SRC-2 Coactivator: a role in human metabolic evolution and disease. Mol Med. (2020) 26(1):45. doi: 10.1186/s10020-020-00168-0
17. Yang Y, He Y, Liu H, Zhou W, Wang C, Xu P, et al. Hypothalamic steroid receptor coactivator-2 regulates adaptations to fasting and overnutrition. Cell Rep. (2021) 37(10):110075. doi: 10.1016/j.celrep.2021.110075
18. Nikolai BC, Jain P, Cardenas DL, York B, Feng Q, McKenna NJ, et al. Steroid receptor coactivator 3 (SRC-3/AIB1) is enriched and functional in mouse and human tregs. Sci Rep. (2021) 11(1):3441. doi: 10.1038/s41598-021-82945-3
19. Jeong JW, Kwak I, Lee KY, White LD, Wang XP, Brunicardi FC, et al. The genomic analysis of the impact of steroid receptor coactivators ablation on hepatic metabolism. Mol Endocrinol. (2006) 20(5):1138–52. doi: 10.1210/me.2005-0407
20. Gao L, Rabbitt EH, Condon JC, Renthal NE, Johnston JM, Mitsche MA, et al. Steroid receptor coactivators 1 and 2 mediate fetal-to-maternal signaling that initiates parturition. J Clin Invest. (2015) 125(7):2808–24. doi: 10.1172/JCI78544
21. York B, Yu C, Sagen JV, Liu Z, Nikolai BC, Wu RC, et al. Reprogramming the posttranslational code of SRC-3 confers a switch in mammalian systems biology. Proc Natl Acad Sci U S A. (2010) 107(24):11122–7. doi: 10.1073/pnas.1005262107
22. Wu RC, Qin J, Yi P, Wong J, Tsai SY, Tsai MJ, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. (2004) 15(6):937–49. doi: 10.1016/j.molcel.2004.08.019
23. Onate SA, Tsai SY, Tsai MJ, O'Malley BW. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. (1995) 270(5240):1354–7. doi: 10.1126/science.270.5240.1354
24. Szwarc MM, Kommagani R, Lessey BA, Lydon JP. The p160/steroid receptor coactivator family: potent arbiters of uterine physiology and dysfunction. Biol Reprod. (2014) 91(5):122. doi: 10.1095/biolreprod.114.125021
25. Kommagani R, Szwarc MM, Vasquez YM, Peavey MC, Mazur EC, Gibbons WE, et al. The promyelocytic leukemia zinc finger transcription factor is critical for human endometrial stromal cell decidualization. PLoS Genet. (2016) 12(4):e1005937. doi: 10.1371/journal.pgen.1005937
26. Szwarc MM, Hai L, Gibbons WE, Peavey MC, White LD, Mo Q, et al. Human endometrial stromal cell decidualization requires transcriptional reprogramming by PLZF. Biol Reprod. (2018) 98(1):15–27. doi: 10.1093/biolre/iox161
27. Noyes RW, Hertig AT, Rock J. Reprint of: dating the endometrial biopsy. Fertil Steril. (2019) 112(4 Suppl 1):e93–115. doi: 10.1016/j.fertnstert.2019.08.079
28. Goodyear MD, Krleza-Jeric K, Lemmens T. The declaration of Helsinki. Br Med J. (2007) 335(7621):624–5. doi: 10.1136/bmj.39339.610000.BE
29. Masuda H, Maruyama T, Hiratsu E, Yamane J, Iwanami A, Nagashima T, et al. Noninvasive and real-time assessment of reconstructed functional human endometrium in NOD/SCID/gamma c(null) immunodeficient mice. Proc Natl Acad Sci U S A. (2007) 104(6):1925–30. doi: 10.1073/pnas.0604310104
30. Maurya VK, Szwarc MM, Fernandez-Valdivia R, Lonard DM, Yong S, Joshi N, et al. Early growth response 1 transcription factor is essential for the pathogenic properties of human endometriotic epithelial cells. Reproduction. (2022) 164(2):41–54. doi: 10.1530/REP-22-0123
31. Szwarc MM, Hai L, Gibbons WE, Mo Q, Lanz RB, DeMayo FJ, et al. Early growth response 1 transcriptionally primes the human endometrial stromal cell for decidualization. J Steroid Biochem Mol Biol. (2019) 189:283–90. doi: 10.1016/j.jsbmb.2019.01.021
32. Robinson MD, McCarthy DJ, Smyth GK. Edger: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. (2010) 26(1):139–40. doi: 10.1093/bioinformatics/btp616
33. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the royal statistical society. Series B (Methodological). (1995) 57(1):289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x
34. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. (2009) 37(1):1–13. doi: 10.1093/nar/gkn923
35. Sherman BT, Huang da W, Tan Q, Guo Y, Bour S, Liu D, et al. DAVID Knowledgebase: a gene-centered database integrating heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC Bioinformatics. (2007) 8:426. doi: 10.1186/1471-2105-8-426
36. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. (2005) 102(43):15545–50. doi: 10.1073/pnas.0506580102
37. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. (2003) 34(3):267–73. doi: 10.1038/ng1180
38. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. (2011) 27(12):1739–40. doi: 10.1093/bioinformatics/btr260
39. Halari CD, Nandi P, Jeyarajah MJ, Renaud SJ, Lala PK. Decorin production by the human decidua: role in decidual cell maturation. Mol Hum Reprod. (2020) 26(10):784–96. doi: 10.1093/molehr/gaaa058
40. Gregory CW, Wilson EM, Apparao KB, Lininger RA, Meyer WR, Kowalik A, et al. Steroid receptor coactivator expression throughout the menstrual cycle in Normal and abnormal endometrium. J Clin Endocrinol Metab. (2002) 87(6):2960–6. doi: 10.1210/jcem.87.6.8572
41. Vienonen A, Miettinen S, Blauer M, Martikainen PM, Tomas E, Heinonen PK, et al. Expression of nuclear receptors and cofactors in human endometrium and myometrium. J Soc Gynecol Investig. (2004) 11(2):104–12. doi: 10.1016/j.jsgi.2003.09.003
42. Brosens JJ, Takeda S, Acevedo CH, Lewis MP, Kirby PL, Symes EK, et al. Human endometrial fibroblasts immortalized by simian virus 40 large T antigen differentiate in response to a decidualization stimulus. Endocrinology. (1996) 137(6):2225–31. doi: 10.1210/endo.137.6.8641169
43. Brosens JJ, Hayashi N, White JO. Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. Endocrinology. (1999) 140(10):4809–20. doi: 10.1210/endo.140.10.7070
44. Vrljicak P, Lucas ES, Lansdowne L, Lucciola R, Muter J, Dyer NP, et al. Analysis of chromatin accessibility in decidualizing human endometrial stromal cells. FASEB J. (2018) 32(5):2467–77. doi: 10.1096/fj.201701098R
45. Lucas ES, Dyer NP, Murakami K, Lee YH, Chan YW, Grimaldi G, et al. Loss of endometrial plasticity in recurrent pregnancy loss. Stem Cells. (2016) 34(2):346–56. doi: 10.1002/stem.2222
46. Li L, Deng CX, Chen Q. SRC-3, a steroid receptor coactivator: implication in cancer. Int J Mol Sci. (2021) 22(9):1–22. doi: 10.3390/ijms22094760
47. Lydon JP, O'Malley BW. Minireview: steroid receptor coactivator-3: a multifarious coregulator in mammary gland metastasis. Endocrinology. (2011) 152(1):19–25. doi: 10.1210/en.2010-1012
48. Krikun G, Mor G, Alvero A, Guller S, Schatz F, Sapi E, et al. A novel immortalized human endometrial stromal cell line with Normal progestational response. Endocrinology. (2004) 145(5):2291–6. doi: 10.1210/en.2003-1606
49. Barbier CS, Becker KA, Troester MA, Kaufman DG. Expression of exogenous human telomerase in cultures of endometrial stromal cells does not alter their hormone responsiveness. Biol Reprod. (2005) 73(1):106–14. doi: 10.1095/biolreprod.104.035063
50. Krikun G, Mor G, Lockwood C. The immortalization of human endometrial cells. Methods Mol Med. (2006) 121:79–83. doi: 10.1385/1-59259-983-4:077
51. Luo Q, Ning W, Wu Y, Zhu X, Jin F, Sheng J, et al. Altered expression of interleukin-18 in the ectopic and eutopic endometrium of women with endometriosis. J Reprod Immunol. (2006) 72(1–2):108–17. doi: 10.1016/j.jri.2006.03.003
52. Rogers LM, Anders AP, Doster RS, Gill EA, Gnecco JS, Holley JM, et al. Decidual stromal cell-derived PGE2 regulates macrophage responses to microbial threat. Am J Reprod Immunol. (2018) 80(4):e13032. doi: 10.1111/aji.13032
53. Schutte SC, Taylor RN. A tissue-engineered human endometrial stroma that responds to cues for secretory differentiation, decidualization, and menstruation. Fertil Steril. (2012) 97(4):997–1003. doi: 10.1016/j.fertnstert.2012.01.098
54. Wu Y, Shi X, Guo SW. The knockdown of progesterone receptor isoform B (PR-B) promotes proliferation in immortalized endometrial stromal cells. Fertil Steril. (2008) 90(4):1320–3. doi: 10.1016/j.fertnstert.2007.10.049
55. Kommagani R, Szwarc MM, Kovanci E, Creighton CJ, O'Malley BW, Demayo FJ, et al. A murine uterine transcriptome, responsive to steroid receptor coactivator-2, reveals transcription factor 23 as essential for decidualization of human endometrial stromal cells. Biol Reprod. (2014) 90(4):75. doi: 10.1095/biolreprod.114.117531
56. Kommagani R, Szwarc MM, Kovanci E, Gibbons WE, Putluri N, Maity S, et al. Acceleration of the glycolytic flux by steroid receptor coactivator-2 is essential for endometrial decidualization. PLoS Genet. (2013) 9(10):e1003900. doi: 10.1371/journal.pgen.1003900
57. Bell SC. Decidualization and insulin-like growth factor (IGF) binding protein: implications for its role in stromal cell differentiation and the decidual cell in haemochorial placentation. Hum Reprod. (1989) 4(2):125–30. doi: 10.1093/oxfordjournals.humrep.a136856
58. Li Q, Kannan A, DeMayo FJ, Lydon JP, Cooke PS, Yamagishi H, et al. The antiproliferative action of progesterone in uterine epithelium is mediated by Hand2. Science. (2011) 331(6019):912–6. doi: 10.1126/science.1197454
59. Murata H, Tsuzuki T, Kido T, Kakita-Kobayashi M, Kida N, Hisamatsu Y, et al. Progestin-induced heart and neural crest derivatives-expressed transcript 2 inhibits angiopoietin 2 via fibroblast growth factor 9 in human endometrial stromal cells. Reprod Biol. (2019) 19(1):14–21. doi: 10.1016/j.repbio.2019.02.005
60. Vasquez YM, Mazur EC, Li X, Kommagani R, Jiang L, Chen R, et al. FOXO1 Is required for binding of PR on IRF4, novel transcriptional regulator of endometrial stromal decidualization. Mol Endocrinol. (2015) 29(3):421–33. doi: 10.1210/me.2014-1292
61. Taylor HS, Arici A, Olive D, Igarashi P. HOXA10 Is expressed in response to sex steroids at the time of implantation in the human endometrium. J Clin Invest. (1998) 101(7):1379–84. doi: 10.1172/JCI1597
62. Taylor HS, Igarashi P, Olive DL, Arici A. Sex steroids mediate HOXA11 expression in the human peri-implantation endometrium. J Clin Endocrinol Metab. (1999) 84(3):1129–35. doi: 10.1210/jcem.84.3.5573
63. Huang P, Deng W, Bao H, Lin Z, Liu M, Wu J, et al. SOX4 Facilitates PGR protein stability and FOXO1 expression conducive for human endometrial decidualization. Elife. (2022) 11:1–24. doi: 10.7554/eLife.72073
64. Kumasaka T, Nishi N, Yaoi Y, Kido Y, Saito M, Okayasu I, et al. Demonstration of immunoreactive somatostatin-like substance in villi and decidua in early pregnancy. Am J Obstet Gynecol. (1979) 134(1):39–44. doi: 10.1016/0002-9378(79)90793-2
65. Lucas ES, Vrljicak P, Muter J, Diniz-da-Costa MM, Brighton PJ, Kong CS, et al. Recurrent pregnancy loss is associated with a pro-senescent decidual response during the peri-implantation window. Commun Biol. (2020) 3(1):1–37. doi: 10.1038/s42003-020-0763-1
66. Murata H, Tanaka S, Tsuzuki-Nakao T, Kido T, Kakita-Kobayashi M, Kida N, et al. The transcription factor HAND2 up-regulates transcription of the IL15 gene in human endometrial stromal cells. J Biol Chem. (2020) 295(28):9596–605. doi: 10.1074/jbc.RA120.012753
67. Mazur EC, Vasquez YM, Li X, Kommagani R, Jiang L, Chen R, et al. Progesterone receptor transcriptome and cistrome in decidualized human endometrial stromal cells. Endocrinology. (2015) 156(6):2239–53. doi: 10.1210/en.2014-1566
68. Li Q, Kannan A, Das A, Demayo FJ, Hornsby PJ, Young SL, et al. WNT4 Acts downstream of BMP2 and functions via beta-catenin signaling pathway to regulate human endometrial stromal cell differentiation. Endocrinology. (2013) 154(1):446–57. doi: 10.1210/en.2012-1585
69. Franco HL, Dai D, Lee KY, Rubel CA, Roop D, Boerboom D, et al. WNT4 Is a key regulator of Normal postnatal uterine development and progesterone signaling during embryo implantation and decidualization in the mouse. FASEB J. (2011) 25(4):1176–87. doi: 10.1096/fj.10-175349
70. Perbal B. The concept of the CCN protein family revisited: a centralized coordination network. J Cell Commun Signal. (2018) 12(1):3–12. doi: 10.1007/s12079-018-0455-5
71. Chen PC, Tai HC, Lin TH, Wang SW, Lin CY, Chao CC, et al. CCN3 Promotes epithelial-mesenchymal transition in prostate cancer via FAK/akt/HIF-1alpha-induced twist expression. Oncotarget. (2017) 8(43):74506–18. doi: 10.18632/oncotarget.20171
72. Liang T, Shen L, Ji Y, Jia L, Dou Y, Guo L. NOV/CCN3 promotes cell migration and invasion in intrahepatic cholangiocarcinoma via miR-92a-3p. Genes (Basel). (2021) 12(11):1–18. doi: 10.3390/genes12111659
73. Li J, Ye L, Owen S, Weeks HP, Zhang Z, Jiang WG. Emerging role of CCN family proteins in tumorigenesis and cancer metastasis (review). Int J Mol Med. (2015) 36(6):1451–63. doi: 10.3892/ijmm.2015.2390
74. Yeger H, Perbal B. CCN Family of proteins: critical modulators of the tumor cell microenvironment. J Cell Commun Signal. (2016) 10(3):229–40. doi: 10.1007/s12079-016-0346-6
75. Winterhager E, Gellhaus A. The role of the CCN family of proteins in female reproduction. Cell Mol Life Sci. (2014) 71(12):2299–311. doi: 10.1007/s00018-014-1556-9
76. Kipkeew F, Kirsch M, Klein D, Wuelling M, Winterhager E, Gellhaus A. CCN1 (CYR61) and CCN3 (NOV) signaling drives human trophoblast cells into senescence and stimulates migration properties. Cell Adh Migr. (2016) 10(1-2):163–78. doi: 10.1080/19336918.2016.1139265
77. Duan L, Schimmelmann M, Wu Y, Reisch B, Faas M, Kimmig R, et al. CCN3 Signaling is differently regulated in placental diseases preeclampsia and abnormally invasive placenta. Front Endocrinol (Lausanne). (2020) 11:597549. doi: 10.3389/fendo.2020.597549
78. Yu Y, Wang W, Lu W, Chen W, Shang A. Inhibin beta-A (INHBA) induces epithelial-mesenchymal transition and accelerates the motility of breast cancer cells by activating the TGF-beta signaling pathway. Bioengineered. (2021) 12(1):4681–96. doi: 10.1080/21655979.2021.1957754
79. Xueqin T, Jinhong M, Yuping H. Inhibin subunit beta A promotes cell proliferation and metastasis of breast cancer through wnt/beta-catenin signaling pathway. Bioengineered. (2021) 12(2):11567–75. doi: 10.1080/21655979.2021.1971028
80. Liu M, Smith R, Liby T, Chiotti K, Lopez CS, Korkola JE. INHBA Is a mediator of aggressive tumor behavior in HER2 + basal breast cancer. Breast Cancer Res. (2022) 24(1):18. doi: 10.1186/s13058-022-01512-4
81. Yi Y, Zhu H, Klausen C, Chang HM, Inkster AM, Terry J, et al. Dysregulated BMP2 in the placenta may contribute to early-onset preeclampsia by regulating human trophoblast expression of extracellular matrix and adhesion molecules. Front Cell Dev Biol. (2021) 9:768669. doi: 10.3389/fcell.2021.768669
82. Jiang S, Chen Q, Liu H, Gao Y, Yang X, Ren Z, et al. Preeclampsia-Associated lncRNA INHBA-AS1 regulates the proliferation, invasion, and migration of placental trophoblast cells. Mol Ther Nucleic Acids. (2020) 22:684–95. doi: 10.1016/j.omtn.2020.09.033
83. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev. (2006) 25(1):99–113. doi: 10.1007/s10555-006-7893-x
84. Jackson HW, Defamie V, Waterhouse P, Khokha R. TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. (2017) 17(1):38–53. doi: 10.1038/nrc.2016.115
85. Ries C. Cytokine functions of TIMP-1. Cell Mol Life Sci. (2014) 71(4):659–72. doi: 10.1007/s00018-013-1457-3
86. Li LB, Louie MC, Chen HW, Zou JX. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett. (2008) 261(1):64–73. doi: 10.1016/j.canlet.2007.11.013
87. Yan J, Erdem H, Li R, Cai Y, Ayala G, Ittmann M, et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. (2008) 68(13):5460–8. doi: 10.1158/0008-5472.CAN-08-0955
88. Zhou G, Hashimoto Y, Kwak I, Tsai SY, Tsai MJ. Role of the steroid receptor coactivator SRC-3 in cell growth. Mol Cell Biol. (2003) 23(21):7742–55. doi: 10.1128/MCB.23.21.7742-7755.2003
89. Gellersen B, Reimann K, Samalecos A, Aupers S, Bamberger AM. Invasiveness of human endometrial stromal cells is promoted by decidualization and by trophoblast-derived signals. Hum Reprod. (2010) 25(4):862–73. doi: 10.1093/humrep/dep468
90. Mei J, Jin LP, Ding D, Li MQ, Li DJ, Zhu XY. Inhibition of IDO1 suppresses cyclooxygenase-2 and matrix metalloproteinase-9 expression and decreases proliferation, adhesion and invasion of endometrial stromal cells. Mol Hum Reprod. (2012) 18(10):467–76. doi: 10.1093/molehr/gas021
91. Ren L, Liu YQ, Zhou WH, Zhang YZ. Trophoblast-derived chemokine CXCL12 promotes CXCR4 expression and invasion of human first-trimester decidual stromal cells. Hum Reprod. (2012) 27(2):366–74. doi: 10.1093/humrep/der395
92. Weimar CH, Macklon NS, Post Uiterweer ED, Brosens JJ, Gellersen B. The motile and invasive capacity of human endometrial stromal cells: implications for Normal and impaired reproductive function. Hum Reprod Update. (2013) 19(5):542–57. doi: 10.1093/humupd/dmt025
93. Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, et al. AIB1, A steroid receptor coactivator amplified in breast and ovarian cancer. Science. (1997) 277(5328):965–8. doi: 10.1126/science.277.5328.965
94. Wu RC, Feng Q, Lonard DM, O'Malley BW. SRC-3 coactivator functional lifetime is regulated by a phospho-dependent ubiquitin time clock. Cell. (2007) 129(6):1125–40. doi: 10.1016/j.cell.2007.04.039
95. Louet JF, Coste A, Amazit L, Tannour-Louet M, Wu RC, Tsai SY, et al. Oncogenic steroid receptor coactivator-3 is a key regulator of the white adipogenic program. Proc Natl Acad Sci U S A. (2006) 103(47):17868–73. doi: 10.1073/pnas.0608711103
96. Meng H, Gonzales NM, Jung SY, Lu Y, Putluri N, Zhu B, et al. Defining the mammalian coactivation of hepatic 12-h clock and lipid metabolism. Cell Rep. (2022) 38(10):110491. doi: 10.1016/j.celrep.2022.110491
97. Homburg R. Polycystic ovary syndrome - from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod. (1996) 11(1):29–39. doi: 10.1093/oxfordjournals.humrep.a019031
98. Dor J, Itzkowic DJ, Mashiach S, Lunenfeld B, Serr DM. Cumulative conception rates following gonadotropin therapy. Am J Obstet Gynecol. (1980) 136(1):102–5. doi: 10.1016/0002-9378(80)90574-8
99. Sagle M, Bishop K, Ridley N, Alexander FM, Michel M, Bonney RC, et al. Recurrent early miscarriage and polycystic ovaries. Br Med J. (1988) 297(6655):1027–8. doi: 10.1136/bmj.297.6655.1027
100. Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M. Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and Normal endometrium: correlation with clinicopathologic parameters and biomarkers. Mod Pathol. (2006) 19(12):1593–605. doi: 10.1038/modpathol.3800696
101. Glaeser M, Floetotto T, Hanstein B, Beckmann MW, Niederacher D. Gene amplification and expression of the steroid receptor coactivator SRC3 (AIB1) in sporadic breast and endometrial carcinomas. Horm Metab Res. (2001) 33(3):121–6. doi: 10.1055/s-2001-14938
102. Kershah SM, Desouki MM, Koterba KL, Rowan BG. Expression of estrogen receptor coregulators in Normal and malignant human endometrium. Gynecol Oncol. (2004) 92(1):304–13. doi: 10.1016/j.ygyno.2003.10.007
103. Sakaguchi H, Fujimoto J, Sun WS, Tamaya T. Clinical implications of steroid receptor coactivator (SRC)-3 in uterine endometrial cancers. J Steroid Biochem Mol Biol. (2007) 104(3–5):237–40. doi: 10.1016/j.jsbmb.2007.03.007
104. Villavicencio A, Bacallao K, Avellaira C, Gabler F, Fuentes A, Vega M. Androgen and estrogen receptors and co-regulators levels in endometria from patients with polycystic ovarian syndrome with and without endometrial hyperplasia. Gynecol Oncol. (2006) 103(1):307–14. doi: 10.1016/j.ygyno.2006.03.029
105. Zelenko Z, Aghajanova L, Irwin JC, Giudice LC. Nuclear receptor, coregulator signaling, and chromatin remodeling pathways suggest involvement of the epigenome in the steroid hormone response of endometrium and abnormalities in endometriosis. Reprod Sci. (2012) 19(2):152–62. doi: 10.1177/1933719111415546
106. Dasgupta S, Rajapakshe K, Zhu B, Nikolai BC, Yi P, Putluri N, et al. Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. (2018) 556(7700):249–54. doi: 10.1038/s41586-018-0018-1
107. Shrestha A, Bruckmueller H, Kildalsen H, Kaur G, Gaestel M, Wetting HL, et al. Phosphorylation of steroid receptor coactivator-3 (SRC-3) at serine 857 is regulated by the p38(MAPK)-MK2 axis and affects NF-kappaB-mediated transcription. Sci Rep. (2020) 10(1):11388. doi: 10.1038/s41598-020-68219-4
108. Dunn CL, Critchley HO, Kelly RW. IL-15 regulation in human endometrial stromal cells. J Clin Endocrinol Metab. (2002) 87(4):1898–901. doi: 10.1210/jcem.87.4.8539
109. Kitaya K, Yasuda J, Yagi I, Tada Y, Fushiki S, Honjo H. IL-15 expression at human endometrium and decidua. Biol Reprod. (2000) 63(3):683–7. doi: 10.1095/biolreprod63.3.683
110. Okada S, Okada H, Sanezumi M, Nakajima T, Yasuda K, Kanzaki H. Expression of interleukin-15 in human endometrium and decidua. Mol Hum Reprod. (2000) 6(1):75–80. doi: 10.1093/molehr/6.1.75
111. Sones JL, Lob HE, Isroff CE, Davisson RL. Role of decidual natural killer cells, interleukin-15, and interferon-gamma in placental development and preeclampsia. Am J Physiol Regul Integr Comp Physiol. (2014) 307(5):R490–2. doi: 10.1152/ajpregu.00176.2014
112. Celona B, Weiner A, Di Felice F, Mancuso FM, Cesarini E, Rossi RL, et al. Substantial histone reduction modulates genomewide nucleosomal occupancy and global transcriptional output. PLoS Biol. (2011) 9(6):e1001086. doi: 10.1371/journal.pbio.1001086
113. Chen Y, Bravo JI, Son JM, Lee C, Benayoun BA. Remodeling of the H3 nucleosomal landscape during mouse aging. Transl Med Aging. (2020) 4:22–31. doi: 10.1016/j.tma.2019.12.003
114. Contrepois K, Coudereau C, Benayoun BA, Schuler N, Roux PF, Bischof O, et al. Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression. Nat Commun. (2017) 8:14995. doi: 10.1038/ncomms14995
115. Feser J, Truong D, Das C, Carson JJ, Kieft J, Harkness T, et al. Elevated histone expression promotes life span extension. Mol Cell. (2010) 39(5):724–35. doi: 10.1016/j.molcel.2010.08.015
116. Hu Z, Chen K, Xia Z, Chavez M, Pal S, Seol JH, et al. Nucleosome loss leads to global transcriptional up-regulation and genomic instability during yeast aging. Genes Dev. (2014) 28(4):396–408. doi: 10.1101/gad.233221.113
117. Liu L, Cheung TH, Charville GW, Hurgo BM, Leavitt T, Shih J, et al. Chromatin modifications as determinants of muscle stem cell quiescence and chronological aging. Cell Rep. (2013) 4(1):189–204. doi: 10.1016/j.celrep.2013.05.043
118. Song S, Johnson FB. Epigenetic mechanisms impacting aging: a focus on histone levels and telomeres. Genes (Basel). (2018) 9(4):1–18. doi: 10.3390/genes9040201
119. Tvardovskiy A, Schwammle V, Kempf SJ, Rogowska-Wrzesinska A, Jensen ON. Accumulation of histone variant H3.3 with age is associated with profound changes in the histone methylation landscape. Nucleic Acids Res. (2017) 45(16):9272–89. doi: 10.1093/nar/gkx696
120. Yu R, Sun L, Sun Y, Han X, Qin L, Dang W. Cellular response to moderate chromatin architectural defects promotes longevity. Sci Adv. (2019) 5(7):eaav1165. doi: 10.1126/sciadv.aav1165
121. O'Sullivan RJ, Kubicek S, Schreiber SL, Karlseder J. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat Struct Mol Biol. (2010) 17(10):1218–25. doi: 10.1038/nsmb.1897
122. Han M, Kim UJ, Kayne P, Grunstein M. Depletion of histone H4 and nucleosomes activates the PHO5 gene in saccharomyces cerevisiae. EMBO J. (1988) 7(7):2221–8. doi: 10.1002/j.1460-2075.1988.tb03061.x
123. Kim UJ, Han M, Kayne P, Grunstein M. Effects of histone H4 depletion on the cell cycle and transcription of saccharomyces cerevisiae. EMBO J. (1988) 7(7):2211–9. doi: 10.1002/j.1460-2075.1988.tb03060.x
124. Chari S, Wilky H, Govindan J, Amodeo AA. Histone concentration regulates the cell cycle and transcription in early development. Development. (2019) 146(19):1475–86. doi: 10.1242/dev.177402
125. Clemente-Ruiz M, Prado F. Chromatin assembly controls replication fork stability. EMBO Rep. (2009) 10(7):790–6. doi: 10.1038/embor.2009.67
126. Prado F, Jimeno-Gonzalez S, Reyes JC. Histone availability as a strategy to control gene expression. RNA Biol. (2017) 14(3):281–6. doi: 10.1080/15476286.2016.1189071
127. Sroga JM, Ma X, Das SK. Developmental regulation of decidual cell polyploidy at the site of implantation. Front Biosci (Schol Ed). (2012) 4(4):1475–86. doi: 10.2741/s347
128. Xu J, Liao L, Ning G, Yoshida-Komiya H, Deng C, O'Malley BW. The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for Normal growth, puberty, female reproductive function, and mammary gland development. Proc Natl Acad Sci U S A. (2000) 97(12):6379–84. doi: 10.1073/pnas.120166297
129. Liu Z, Liao L, Zhou S, Xu J. Generation and validation of a mouse line with a floxed SRC-3/AIB1 allele for conditional knockout. Int J Biol Sci. (2008) 4(4):202–7. doi: 10.7150/ijbs.4.202
130. Soyal SM, Mukherjee A, Lee KY, Li J, Li H, DeMayo FJ, et al. Cre-mediated recombination in cell lineages that express the progesterone receptor. Genesis. (2005) 41(2):58–66. doi: 10.1002/gene.20098
Glossary
AAALAC, association for the assessment and accreditation of laboratory animal care; AD, activation domain; AIB1, amplified in breast cancer 1; ANOVA, analysis of variance; ATCC, american type culture collection; BHLH, basic helix loop helix; CCN2, cellular communication network factor 2; CCN3, cellular communication network factor 3; DAPI, 4′,6′-diamidino-2-phenylindole; DAVID, database for annotation, visualization, and integrated discovery; DCN, decorin; DMEM, Dulbecco's modified eagle's medium; DMSO, dimethyl sulfoxide; E2, estradiol; ECM, extracellular matrix; EMT, epithelial mesenchymal transition; EPC, 17β-estradiol, medroxyprogesterone acetate, 2′-O-dibutyryladenosine-3′, 5′ cAMP; EPL, early pregnancy loss; FC, Fold change; FDR, false discovery rate; FOXO1, forkhead box O1A; FPKM, fragments per kilobase of exon per million mapped fragments; GE, glandular epithelium; GEO, gene expression omnibus; GSEA, gene set enrichment analysis; GO, gene ontology; HAT, histone acetyl transferase; H3AC21, H3A clustered histone 21; H3C1, H3 clustered histone 1; H3C7, H3 clustered histone 7; H3C10, H3 clustered histone 10; H4C3, H4 clustered histone 3; H4C4, H4 clustered histone 4; HAND2, heart- and neural crest derivatives-expressed protein 2; HESC, human endometrial stromal cell; HOXA, Homeobox A; HRP, horse radish peroxidase; IACUC, institutional animal care and use committee; IL15, Interleukin 15; IGFBP-1, insulin like growth factor binding protein-1; INHBA, inhibin beta A; IRB, Institutional review board; ITS-A, insulin, transferrin, selenite and sodium pyruvate; LXXLL, Leucine-X-X-leucine-leucine; KEGG, kyoto encyclopedia of genes and genomes; MSIGDB, molecular signatures database; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide; NCBI, national center for biotechnology information; NCOA, Nuclear coactivator; NT, Non targeting; P4, Progesterone; P300/CBP, EP300/CREB-binding protein; PAS, Per-Arnt-Sim; PBS, phosphate buffered saline; PCA, principal component analysis; PCOS, polycystic ovary syndrome; PGR, progesterone receptor; PGR-CRE, progesterone receptor cre; PRL, prolactin; PTMs, posttranslational modifications; PVDF, polyvinylidene difluoride; RID, receptor interaction domain; RIN, RNA integrity number; RNA-seq, RNA sequencing; RPL, recurrent pregnancy loss; Q, polyglutamine; QPCR, quantitative polymerase chain reaction; SCARA5, Scavenger receptor class A member 5; Scid, Severe combined immunodeficiency; SD, Standard deviation; SDECs, singly dispersed endometrial cells; SDS-PAGE, sodium dodecyl sulfate polyacrylamide; SE, standard error; SFBS, stripped fetal bovine serum; siRNA, small interfering RNA; SOX4, SRY-box transcription factor 4; SST, somatostatin; SRC-1, steroid receptor coactivator-1; SRC-2, steroid receptor coactivator-2; SRC-3, Steroid receptor coactivator-3; STR, short tandem repeat; TBS-T, tris-buffered saline with Tween 20; T-HESCs, Telomerase-transformed human endometrial stromal cells; TIF-2, Transcription intermediary factor; TIMP1, Tissue inhibitor of metalloproteinases 1; uNK, Uterine natural killer cells; WNT4, Wingless/integrated 4.
Keywords: steroid receptor coactivator-3, human endometrium, stromal cells, decidualization, RNA-sequencing
Citation: Maurya VK, Szwarc MM, Lonard DM, Gibbons WE, Wu S, O’Malley BW, DeMayo FJ and Lydon JP (2022) Decidualization of human endometrial stromal cells requires steroid receptor coactivator-3. Front. Reprod. Health 4:1033581. doi: 10.3389/frph.2022.1033581
Received: 31 August 2022; Accepted: 7 November 2022;
Published: 24 November 2022.
Edited by:
Jan Tesarik, MARGen Clinic, SpainReviewed by:
Ren-Wei Su, South China Agricultural University, ChinaVinay Shukla, University of Kansas Medical Center, United States
© 2022 Maurya, Szwarc, Lonard, Gibbons, Wu, O'Malley, DeMayo and Lydon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: John P. Lydon jlydon@bcm.edu
Specialty Section: This article was submitted to Assisted Reproduction, a section of the journal Frontiers in Reproductive Health